Products

Carbopol^® Polymers

Product Overview and Recommendations

	Residual Solvent			Product Type
Carbopol® Polymer	Benzene	Ethyl Acetate	Cosolvent1	Homopolymer	Copolymer	Interpolymer	Viscosity, cP (0.5 wt% at pH 7.5)
71G NF		•		•			4,000 - 11,000
971P NF		•		•			4,000 - 11,000
974P NF		•		•			29,400 - 39,400
980 NF			•	•			40,000 - 60,000
981 NF			•	•			4,000 - 10,000
5984 EP			•	•			30,500 - 39,400
Ultrez 10 NF			•			•	45,000 - 65,000
934 NF	•			•			30,500 - 39,400
934P NF	•			•			29,400 - 39,400
940 NF	•			•			40,000 - 60,000
941 NF	•			•			4,000 - 10,000
1342 NF	•				•		9,500 - 26,5002
1 Colsolvent system made using cyclohexane and ethyl acetate 2 1.0 wt% Carbopol® homopolyers are polymers of acrylic acid crosslinked with allyl sucrose or allyl pentaerythritol Carbopol® copolymers are polymers of acrylic acid and C10-C30 alkyl acrylate crosslinked with allyl pentaerythritol Carbopol® interpolymers are a carbomer homopolymer or copolymer that contains a block copolymer of polyethylene glycol and a long chain alkyl acid ester

Due to regulatory restrictions on the use of benzene in pharmaceutical formulations, Lubrizol recommends that carbomers polymerized in either ethyl acetate or a cosolvent mixture of ethyl acetate and cyclohexane be used for all new drug development projects.

Additionally, it may be desirable to substitute a benzene polymerized carbomer with a non-benzene polymerized carbomer in a pharmaceutical formulation. The following table shows recommended substitutes for the benzene grade Carbopol^® products based on viscosity criteria. The substitute products are polymerized in either ethyl acetate or a cosolvent mixture of ethyl acetate and cyclohexane. If a substitution is made in a pharmaceutical formulation, it is recommended that key performance properties be ascertained and regulatory considerations be taken into account. Depending on the desired dosage requirements, other Carbopol^® polymers may be suitable alternatives.